ISPOR - PCN49 Biosimilar Trastuzumab Mono- and Pertuzumab Combination Therapy in Metastatic Breast Cancer: Cost Efficiency and Expanded Access Modeling

PCN49 Biosimilar Trastuzumab Mono- and Pertuzumab Combination Therapy in Metastatic Breast Cancer: Cost Efficiency and Expanded Access Modeling

Abstract

Authors

A. McBride A. Fuentes-Alburo K. MacDonald I. Abraham

Full Text Cite This Article

Back to Volume 24, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now